Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 1997

View Archived Issues

Glaxo Wellcome discloses heteroaromatic protein tyrosine kinase inhibitors

Short-acting beta1-adrenoceptor blockers from U. of Melbourne

ET antagonists disclosed by Merck KGaA

Microcide reveals new cephalosporins active against resistant organisms

Opioid antagonists/agonists described by Toray

Banyu discovers potent new antitumor agent

Natural antitumor compounds described by Banyu

Inhibitors of 5alpha-reductase from Kyowa Hakko

Antiviral pyrimidine nucleosides described by Yamasa

Prodrugs of nitrogen mustard with selective antitumor activity

MP-52 to be developed worldwide by HMR

NDA to be submitted in Japan for nevirapine

Glaxo to submit NDA in Japan for lamivudine in hepatitis

Tamsulosin cleared by FDA

Protease inhibitors in Japan

PharmaSciences and BTG extend license for hydrogel drug delivery technology

Fujisawa and Solvay sign marketing agreement for antidepressant

IDEC Pharmaceuticals: Q1 1997 highlights

Novel antiinflammatory agent from Parke-Davis

Sano: Q1 1997 highlights

Neutralase effective for heparin reversal in CAB

GalaGen: Q1 1997 highlights

OXiGENE: Q1 1997 highlights

Algos: Q1 1997 highlights

BY-963 for delineation of myocardial perfusion during cardiac surgery

Clevidipine for controlling hypertension after CABG

Favorable hemodynamic profile of aptiganel during general anesthesia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.